IRMD Stock Recent News
IRMD LATEST HEADLINES
iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.
iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.
IRadimed Corporation continues to re-rate to the downside despite robust fundamentals last quarter. Despite this, the market may have discounted the stock correctly looking at revenue, EPS estimates in our opinion.
IRadimed Corporation (NASDAQ:IRMD ) Q3 2022 Earnings Conference Call November 3, 2022 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Operator Welcome to the IRadimed Corporation Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRadimed Corporation (NASDAQ:IRMD ) Q2 2022 Earnings Conference Call July 29, 2022 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Jack Glenn – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
WINTER SPRINGS, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRadimed presents us with the alternative risk premia that investors are rewarding in FY22. Bottom-line fundamentals are strengthening whilst the stock has diverged away from the medtech sector.
iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.